Form 4: Bolt Biotherapeutics Executive Reports Stock Transaction
Insider Transaction (Form 4)
Sarah Nemec, Senior VP, Finance and PAO of Bolt Biotherapeutics, Inc., reported multiple transactions in common stock on September 16, 2026.
Summary
- Open-market purchase: acquired 509 Common Stock at $3.88 ($1,973) on June 5, 2026; holds 1,924 after (Direct).
- Open-market sale: disposed of 843 Common Stock at $3.77 ($3,181) on September 16, 2026; holds 24,081 after (Direct).
- Open-market sale: disposed of 2,922 Common Stock at $3.32 ($9,696) on September 17, 2026; holds 21,159 after (Direct).
- Open-market sale: disposed of 4,077 Common Stock at $3.24 ($13,195) on September 18, 2026; holds 17,082 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai notes net insider selling of $24,099 across mixed open-market transactions.
Insider Transactions
Sarah Nemec — Officer (Senior VP, Finance and PAO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-06-05 | Open-market purchase | Common Stock | 509 | $4 | $2.0K | 1,924 |
| 2026-09-16 | Open-market sale | Common Stock | 843 | $4 | $3.2K | 24,081 |
| 2026-09-17 | Open-market sale | Common Stock | 2,922 | $3 | $9.7K | 21,159 |
| 2026-09-18 | Open-market sale | Common Stock | 4,077 | $3 | $13.2K | 17,082 |
Key Dates
| Date | Description |
|---|---|
| 2026-06-05 | Open-market purchase (509 shares) |
| 2026-09-16 | Open-market sale (843 shares) |
| 2026-09-17 | Open-market sale (2,922 shares) |
| 2026-09-18 | Open-market sale (4,077 shares) |
Keywords
insider transaction, Form 4, BOLT, Bolt Biotherapeutics, Inc., net selling, Sarah Nemec
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.